公司资料
AbbVie Inc 股价、新闻与催化剂
- 股票代码:
- ABBV
- 交易所:
- NYSE
- 行业:
- Biopharma, Immunotherapy, CNS
- 所在地:
- United States
股票表现
250.33 USD (+0.35%)
收盘价
最后更新: 2026年8月17日
381B USD
市值
股价为何变动
As of Aug 17, 2026, ABBV closed up 0.35% at $250.33. No new same-company headline was identified in the current news window.
公司概览
业务概览
AbbVie is a large biopharmaceutical company with major franchises in immunology, aesthetics, neuroscience, and oncology. Its identity has evolved from a single-product legacy into a broader diversified growth story.
所在地与行业分类
Headquartered in the United States and listed on NYSE, AbbVie has a global commercial footprint with meaningful exposure to both developed and international markets. It sits firmly in large-cap biopharma.
商业模式特征
AbbVie combines mature cash flow with pipeline reinvestment and lifecycle management. Investors focus on immunology growth, aesthetic product performance, patent runoff, and the replacement cycle across its core portfolio.
生物医药行业定位
AbbVie is a mature large-cap biotech-like pharma with a strong commercial base and ongoing catalyst sensitivity. It is not binary, but pipeline, label, and patent developments still matter for valuation.
未来催化剂
- AbbVie’s key near-term catalysts are pivekimab sunirine’s BLA path, Rinvoq label-expansion opportunities, and continued Skyrizi momentum. The next checkpoint matters because it tells investors whether the program is still moving on schedule or whether the timeline needs to be reset. A clean outcome also makes it easier to think about the next regulatory or label step instead of just the current filing.
近期新闻
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。